Share

Covid-19 update: Patient safety is paramount

Patients must come first: EORTC will take all measures necessary to ensure that trials continue

Following on from the actions taken by a number of European countries to try to halt the spread of the COVID-19 pandemic, EORTC is liaising with its members to monitor the developments in their institutions and countries.

“Patient safety is paramount to us, and we will do everything we can to ensure that patients in trials still receive treatment for their disease,” says Dr Denis Lacombe, Director General of EORTC. “As Europe starts to close down its borders, we are watching the supply of cancer drugs for trials, as well any other emerging issues and limitations related to clinical research.”

EORTC will continue to provide services and to ensure that there is minimal impact on its activities. EORTC HQ staff have been requested to work from home until 3 April.

“We will do whatever we can to safeguard the health and safety of patients on EORTC clinical trials, our staff, and our members. Our thoughts are with those families who have been greatly affected by this pandemic, and we will do all we can to help and protect them.”

Update: Following the announcement of the Belgian Federal Government on March 27, EORTC staff has been working from home until further notice.

Back to news list

Related News

  • EORTC Quality of Life Group celebrating 40 years

  • Results of two EORTC studies have been published in NEJM and the Lancet Oncology

  • Interview with Winette van der Graaf: enhanced patient participation in trials may help make cancer research more heterogeneous

  • New results, updates, and forthcoming EORTC trials in melanoma, soft tissue sarcoma, head and neck, testicular and lung cancer presented at ESMO 2022

  • Important new data from EORTC trials to be presented at ESMO 2022

  • EORTC Item Library provides considerable coverage of CTCAE side effects, new study finds

  • EORTC Completes Patient Recruitment to Study of Treatment for unresectable or metastatic melanoma

  • In Memoriam: Dr Martin Charles Mihm

  • The 1500th patient has been enrolled in the E²-RADIatE cohort OLIGOCARE (RP-1822)

  • PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation